Chris Klee has 30 years of pharmaceutical industry experience in finance. He has held multiple roles within the Novartis organization. In 2005, Mr. Klee joined the Novartis Institutes for BioMedical Research (NIBR) as Chief Financial Officer and later assumed an expanded role as CFO & Chief Operating Officer. During his tenure at NIBR, he served on boards of several biotech companies. Mr. Klee was the CFO of Novartis USA (2016-2021) before he joined Aditum Bio.
Chris graduated from the Business School of the University of St. Gallen in Switzerland with a degree in Finance and Economics.